NGS studies have uncovered an ever-growing catalog of human variation while leaving 12 an enormous gap between observed variation and experimental characterization of variant 13 function. High-throughput screens powered by NGS have greatly increased the rate of variant 14 functionalization, but the development of comprehensive statistical methods to analyze screen 15 data has lagged behind. In the massively parallel reporter assay (MPRA), short barcodes are 16 counted by sequencing DNA libraries transfected into cells and output RNA in order to 17 simultaneously measure the shifts in transcription induced by thousands of genetic variants.
2 23 We have developed an extensive framework for the analysis of NGS functionalization 24 screens available as an R package called malacoda (available from 25 github.com/andrewGhazi/malacoda). Our software implements a probabilistic, fully Bayesian 26 model of screen data. The model uses the negative binomial distribution with gamma priors to 27 model sequencing counts while accounting for effects from input library preparation and 28 sequencing depth. The method leverages the high-throughput nature of the assay to estimate the 29 priors empirically. External annotations such as ENCODE data or DeepSea predictions can also 30 be incorporated to obtain more informative priors -a transformative capability for data 31 integration. The package also includes quality control and utility functions, including automated 32 barcode counting and visualization methods. 33 To validate our method, we analyzed several datasets datasets using malacoda and 34 alternative MPRA analysis methods. These data include experiments from the literature, 35 simulated assays, and primary MPRA data. We also used luciferase assays to experimentally 36 validate the strongest hits from our primary data, as well as variants for which the various 37 methods disagree and variants detectable only with the aid of external annotations.
Introduction 54
The advent of next generation sequencing (NGS) has generated an explosion of observed 55 genetic variation in humans. Variants with unclear effects greatly outnumber those with obvious, 56 severe impact; the 1000 Genomes Project [1] has estimated that a typical human genome has 57 roughly 150 protein-truncating variants, 11,000 peptide-sequence altering variants, and 500,000 58 variants falling into known regulatory regions. Simultaneously, genome-wide association studies 59 (GWAS) have found strong statistical associations between thousands of noncoding variants and 60 hundreds of human phenotypes [2, 3] . Traditional methods of assessing the regulatory impact of 61 variants are slow and low-throughput: luciferase reporter assays require multiple replications of 62 cloning individual genomic regions, transfection into cells, and measurement of output intensity. variants. The diagram shows six constructs with two variants, but in practice the size of the 78 oligonucleotide library is only limited by cost. A typical MPRA has tens to hundreds of 79 thousands of oligonucleotides to assay thousands of variants.
80
MPRA have successfully identified many transcriptionally functional variants [5, 6, 7] , 81 but the accompanying statistical analyses have been rudimentary. Initial studies focused on the 82 computation of the "activity" for each barcode in each RNA sample. This involves averaging 83 across depth-adjusted counts to compute a normalizing DNA factor for each barcode, then 84 dividing RNA counts by the DNA factor and taking the log of this ratio. Then a t-test is used to 85 compare the activity measurements for each allele, followed by assay-wide multiple-testing Genome-wide databases like ENCODE and computational predictors like DeepSea contain real 100 information about variant effects, but the method for incorporating this information into a 101 statistical framework for experimental analysis of variants has been unclear. 102 We hypothesized that a Bayesian approach to high throughput NGS screens such as 103 MPRA would improve statistical sensitivity and specificity and yield more accurate estimates of 104 variant function, particularly when incorporating prior information. The Bayesian approach 105 offers a flexible modeling system that can flexibly fit hierarchical model structures of count data 106 while also directly accounting for experimental sources of variation. The Bayesian approach also 107 enables the integration of prior information and probabilistic modelling of dispersion parameters.
108
These advantages offer significant improvements in statistical efficiency and provide advantages 109 for formulating systems-level hypotheses --for example, the impact of specific transcription 110 factors --that are absent from other approaches. Here we present malacoda, an end-to-end 111 Bayesian statistical framework that addresses the gaps in the prior approaches while providing 112 novel methods for incorporating prior information. The malacoda method centers on MPRA but 113 also has potential extension to a broad array of NGS-based high-throughput screens. We 6 114 establish the superior performance of malacoda on MPRA compared to alternatives using 115 simulation studies. Then, we apply the method to previously published findings to make new 116 biological discoveries that we explore in the paper. We also apply malacoda to primary MPRA 117 studies that we performed. The results demonstrate that using malacoda we can discover 118 biologically important findings that were missed by prior approaches. We have made the well as due to the inherent noise in library preparation. The RNA measurements also vary 137 according to sequencing depth, but they are also affected by the DNA input concentration and 138 the inherent transcription rate of their associated region of genomic context. Figure 2A shows a 139 subset of a typical MPRA dataset, with two barcodes of each allele for two variants and several 140 columns of counts. We find that typically MPRA are performed with four to six RNA 141 sequencing replicates and a smaller number of DNA replicate samples. Figure 2B The negative binomial distribution is a natural choice for modelling NGS count data 152 given its ability to accurately fit overdispersed observations frequently seen in sequencing data 153 [12] . Briefly, the observed dispersion in NGS count data usually exceeds that expected from 154 simpler binomial or Poisson models. We chose gamma distributions as priors for several reasons.
155
They have the appropriate [0,∞) support, and for a non-negative random variable whose 194 In order to incorporate external knowledge, the malacoda method also allows users to 195 provide arbitrary annotations to supplement the analysis. Figure 2C figure 2C shows this for only a single informative annotation on 207 the horizontal axis, the code allows for an arbitrary number of continuous predictors to be used. 
Results

247
Simulation Studies 248 We evaluated our simulation results in three ways. First, we focused on the accuracy of 249 transcription shift estimates. Figure 3A shows the results of analyzing one simulated dataset, 250 with the true value of the simulation's transcription shift plotted on the x-axis, with the model 251 estimates on the y-axis. For each fit of each simulation using each analysis method, we analyzed 252 performance using two metrics: standard deviation of estimates for truly non-functional variants 253 at zero (center dots, lower is better) and correlation with the truth for truly functional variants 254 with nonzero effects (off-center dots, higher is better). Second, we also computed area under the curve (AUC) for each method. Bayesian 265 methods such as malacoda explicitly do not consider a null hypothesis and therefore do not 266 output p-values; in order to create an analogous output quantity to derive an ROC curve we 267 instead computed one minus the minimum HDI width necessary to include zero as a credible 268 transcription shift value to distinguish true and false positives. Figure 3B shows the ROC curves 13 269 by method for a randomly chosen simulation with ten barcodes per allele, 5% truly functional 270 variants, and 3000 variants. Figure 3C shows that across all simulations with these 271 characteristics, malacoda consistently showed the highest median AUC, highest correlation with 272 the truth for functional variants, and the lowest spread among estimates of truly nonfunctional 273 variants. Other simulation grid points are shown in S2 Appendix, and these display similar 274 patterns.
275
In order to examine the performance of malacoda on real data, we applied the various 276 methods to both the Ulirsch data [5] and to our own primary dataset. Unlike the case with 277 simulations, the underlying true values are not known. However, inter-method consensus can 278 serve as a performance metric --alternative methods presumably fail in different ways, so if they 279 tend to disagree with one another but agree with malacoda, that would imply that malacoda is 280 working well across the cases where others fail. Indeed, Figure 4 shows that the other methods 281 tend to correlate with malacoda better than the other alternatives. The one exception is when 282 applied to our dataset, mpralm tends to agree best with the t-test method. Given that linear 283 models underlie both mpralm and the t-test method, it seems plausible that they would 284 sometimes show similar results. The number of luciferase reporter assays we performed was not enough to overcome the 292 amount of noise inherent to light intensity-based measurements, thus we did not have enough 293 data to clearly demonstrate that any of the MPRA analysis methods outperform the others in 294 terms of correlation with luciferase results. However, the results show that the various methods 295 are consistent with MPRA-based estimates Figure 3D , providing further evidence that MPRA 296 results are biologically realistic.
297
We closely inspected a particular biological discovery to demonstrate malacoda's ability 298 to identify low-signal variants. We developed a fully Bayesian framework for the analysis of NGS high throughput 317 screens with specific application to MPRA studies. The method is an advance in statistical and binding data as well as evidence of association with platelet count in healthy humans.
331
There are downsides to our method. First, Bayesian methods that estimate a joint 332 posterior on many parameters by MCMC are significantly slower than optimization approaches.
333
To address this, we fit our models with Stan [24] , which allows us to perform a first pass fit with 
